TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6825391
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Asproclear
Study: 6825391
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg compressed ASA
Study: 31476451
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.5 g/day)
Study: 23788270
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with irinotecan or temozolomide after 2 chemotherapy cycles (8 weeks)
Study: 10754621
Drug: Crystalloid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid infusion at the same rates as group C
Study: 8796792
Drug: 0.125 mg/2
Normalized name: digoxin 0.125 mg/2.5 mL (125 mcg/2.5 mL) (50 mcg/mL) ORAL SOLUTION, ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/2 ml PGE2 gel
Study: 24130356
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin
Study: 3076707
Drug: Weekly antimalarial
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly antimalarial chemoprophylaxis (chloroquine)
Study: 3709032
Drug: Tripelennamine HCl
Normalized name: tripelennamine HCl
DrugBank: Tripelennamine (DB00792)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tripelennamine HCl 50 mg
Study: 3709032
Drug: Tripelennamine HCl
Normalized name: tripelennamine HCl
DrugBank: Tripelennamine (DB00792)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tripelennamine HCl 100 mg
Study: 7028897
Drug: S-carboxymethylcysteine syrup
Normalized name: S-carboxymethylcysteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine syrup (SCMC)
Study: 19903345
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention consisting of three visits to a Personal Vitality Coach (PVC) and a Vitality Exercise Programme (VEP) over 6 months, including weekly guided yoga and aerobic workout sessions, and encouragement for vigorous physical activity.
Study: 2807448
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (ORT) introduced by health volunteers
Study: 23756962
Drug: Toltrazuril 5
Normalized name: Toltrazuril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toltrazuril 5 % suspension (Baycox®, Bayer)
Study: 8862223
Drug: Urinary albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary albumin excretion (UAE)
Study: 7013056
Drug: Levamisole 100
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole 100 mg
Study: 10200005
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone at 2 mg/kg/dose (maximum 120 mg/dose) twice daily
Study: 30626424
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) combined with fluoxetine (20 mg/day)
Study: 10714475
Drug: 10-day clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day clarithromycin 500 mg bid
Study: 12369756
Drug: Glimepiride tablet
Normalized name: Glimepiride Tablets
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride tablet (1.0 mg)
Study: 11772908
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg once daily
Study: 2769581
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) mean daily intake of 2.44 grams
Study: 8366819
Drug: Traditional immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional immunization schedule (group B): immunized at 4 days, 1 month, and 6 months of life with 10 micrograms of recombinant HBV vaccine (Engerix B, SKF)
Study: 9987495
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (Bakkevold trial)
Study: 7838635
Drug: Small volume
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small volume feeding (4 mL/kg)
Study: 9431834
Drug: Salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 8 mg
Study: 2856892
Drug: Nadolol 20
Normalized name: nadolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 20 mg
Study: 8004841
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg
Study: 10852450
Drug: ACTH infusion
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH infusion (Cortrosyn, 50 microg/h) in E2-replaced women
Study: 26843092
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g CLA (75 % c9,t11‐CLA, 87 % purity)
Study: 21805567
Drug: 6 Fr
Normalized name: Catheter 16 Fr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Fr catheters with manual injection
Study: 2874047
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of salbutamol 0.1 mg/kg followed by inhalation of 0.25 mg of ipratropium bromide
Study: 2874047
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of ipratropium bromide and salbutamol
Study: 24089589
Drug: Testosterone Treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Treatment (TT)
Study: 30537937
Drug: BEATVIC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEATVIC therapy (body-oriented resilience therapy using kickboxing exercises)
Study: 11583479
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg
Study: 12855319
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg q.i.d.
Study: 10501793
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g twice daily for 12 months
Study: 10501793
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g twice daily for 12 months plus intranasal calcitonin 400 IU/day for the first month and then 200 IU/day for 11 months
Study: 1835301
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel, 0.5 mg
Study: 1835301
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (meta-analysis)
Study: 20634186
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (30 mg, oral)
Study: 15123461
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative intraperitoneal chemotherapy (EPIC) plus systemic chemotherapy after complete cytoreductive surgery
Study: 15123461
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone after complete cytoreductive surgery
Study: 25358490
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of a polyphenol-rich treatment extracted from fruit and vegetables (Mediterranean diet) daily for 12 weeks
Study: 22937895
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily
Study: 12106929
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion in the IRA after one year
Study: 16932286
Drug: Intravenous bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bisphosphonates (currently under investigation)
Study: 20424456
Drug: Diamorphine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine treatment
Study: 27261562
Drug: Disorder-specific Cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder-specific Cognitive Behaviour Therapy (DS‐CBT)
Study: 21945130
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS)
Study: 30683137
Drug: Propofol (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3-5 mg/kg/h intravenous injection for the duration of surgery)
Study: 9187591
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mmol (7.5 g) daily for 3 days
Study: 15881479
Drug: Moxifloxacin 0.5%
Normalized name: Moxifloxacin 0.5%, Bromfenac 0.075% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% ophthalmic solution
Study: 19167587
Drug: Rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone maleate (reference formulation)
Study: 20458090
Drug: Cholecalciferol treatment
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol treatment (2000 IU/d)
Study: 27487966
Drug: Nurse-initiated antiviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nurse-initiated antiviral therapy
Study: 27487966
Drug: Physician-initiated antiviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Physician-initiated antiviral therapy
Study: 8238193
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg/day)
Study: 1053438
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate nasal aerosol (400 micrograms daily)
Study: 23399032
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity Promotion Programme (PAPP) for 60 minutes, twice a week during three months
Study: 22610495
Drug: ACM-to-CC (n=21)
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-to-CC (n=21)
Study: 22610495
Drug: CC-to-CC (n=28)
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-to-CC (n=28)
Study: 20718174
Drug: Estimated dose
Normalized name: desmopressin Metered Dose Nasal Spray [Stimate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated dose based on gland size
Study: 14988669
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon (considered for future treatment)
Study: 27190087
Drug: Linagliptin plus
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin plus pioglitazone 30 mg
Study: 27190087
Drug: Linagliptin plus
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin plus pioglitazone 45 mg
Study: 31713160
Drug: Linagliptin monotherapy
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin monotherapy
Study: 22409999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received insulin if blood glucose >14 mmol/l (n = 8)
Study: 22409999
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin administration (n = 9)
Study: 1330437
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors
Study: 11345028
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of Ukrain
Study: 8940324
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (0.7 g/kg) in women on ERT
Study: 17905660
Drug: Low-dose mifepristone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mifepristone
Study: 12230417
Drug: Hormone use
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone use (first 6 months)
Study: 12230417
Drug: Estrogen dose
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen dose
Study: 7606199
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 800 mg/m2/day
Study: 15506554
Drug: 3.5 mL
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mL (26.25 mg) of 0.75% glucose-free ropivacaine
Study: 15506554
Drug: 4.5 mL
Normalized name: 4.5 ML Triferic 1.5 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mL (33.75 mg) of 0.75% glucose-free ropivacaine
Study: 19226424
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg once daily for 2 years
Study: 10593430
Drug: Dalteparin once
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin once daily (mean 4631 IU anti-factor Xa units/day)
Study: 23420115
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg
Study: 10665784
Drug: Air treatment
Normalized name: GLYCERIN 3.88 mg in 1 mL TOPICAL SHAMPOO [HAIR TREATMENT PREMIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air treatment in 10 fractions (total dose of 40 Gy)
Study: 9203726
Drug: Oral poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliovirus vaccine (OPV1, OPV2, OPV3, OPV4)
Study: 6743447
Drug: morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine sulphate 2 mg
Study: 23816491
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release gabapentin (G-ER)
Study: 22011892
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional treatment, filled with vertically condensed gutta-percha)
Study: 22961865
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control)
Study: 25377269
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (0.5 μg/kg/h continuous infusion)
Study: 19403992
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1,800 mg daily
Study: 14500150
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (25 mL saline)
Study: 14500150
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (25 mL 0.25% bupivacaine)
Study: 15213620
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered from 2 days before until day 7 after esophagectomy, standard doses
Study: 15896352
Drug: Methylphenidate 20
Normalized name: METHYLPHENIDATE 20MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 20 mg
Study: 9315419
Drug: Vaginal contraceptive
Normalized name: VCF Vaginal Contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9 (N-9)
Study: 21884947
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Study: 9858441
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy from a physiotherapist in primary care
Study: 16283538
Drug: Infusion rates
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rates of the drug (individualized to achieve the same target concentration)
Study: 7216144
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg FK 33‐824 i.m. after saline i.v.
Study: 4607227
Drug: Intranasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunization with inactivated influenza virus vaccine (placebo)
Study: 7216144
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Study: 15105197
Drug: Interactive music
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive music therapy
Study: 12534446
Drug: Iloprost administered
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost administered for 21 days in PAD patients
Study: 30488510
Drug: HPV vaccination
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccination (3 doses)
Study: 1899364
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rt-PA with heparin and aspirin
Study: 7052115
Drug: Amniotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotomy and intravenous oxytocin
Study: 7052115
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) vaginal tablet (3 mg)
Study: 10830223
Drug: Cyclosporine +
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine + Azathioprine (1 mg/kg/day)
Study: 20431040
Drug: Cyclosporine monotherapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine monotherapy
Study: 24686045
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 8 mg/2 mL with 50 mL IV normal saline
Study: 20051371
Drug: Oral DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral DFMO (500 mg/m2/day)
Study: 19011281
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (ALA) 6.0 g/day
Study: 10639356
Drug: Teicoplanin (TEC)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (TEC) administered in monolateral and bilateral TKR.
Study: 11967252
Drug: Celecoxib, 200
Normalized name: Celecoxib, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 200 mg twice daily (n=91)
Study: 25781025
Drug: Intravenous Zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Zoledronic Acid (ZA), 2 doses, 3 weeks apart
Study: 3300248
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release isosorbide dinitrate (ISDN), 20 to 40 mg twice daily
Study: 8222739
Drug: Controlled-release ketoprofen
Normalized name: ketoprofen Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release ketoprofen tablets (200 mg)
Study: 10632414
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg)
Study: 1991685
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality (CM) treatment with Cisplatin 50 mg IV weekly during radiotherapy.
Study: 1991685
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) without chemotherapy.
Study: 18292445
Drug: Postoperative celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative celecoxib (2 celecoxib 200 mg p.o. after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2 and #3)
Study: 26407878
Drug: Fentanyl moderate
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl moderate dose (24 μg/kg)